tiprankstipranks
Trending News
More News >

Skye Bioscience debuts ‘Anatomy of Progress’ nimacimab development update series

Skye Bioscience (SKYE) announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association’s 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. In this four-part video series, Skye discusses unmet needs in the obesity therapeutic space, advantages and benefits of its peripheral CB1-receptor-targeting antibody, which is designed to support healthy weight loss, and development progress of this novel CB1-inhibiting molecule.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1